Embedded Files
COVID
COVID
We are working closely with our collaborator, Dr. Jason Knight to leverage our strengths in inflammation and thrombosis, two processes at the heart of severe COVID-19 illness to understand this disease, and develop potential new treatments.
We are working closely with our collaborator, Dr. Jason Knight to leverage our strengths in inflammation and thrombosis, two processes at the heart of severe COVID-19 illness to understand this disease, and develop potential new treatments.
1. Biomarker - We discovered a blood neutrophil inflammation signature in the blood of patients with COVID-19 infection that can be targeted for treatment of this dangerous disease.
1. Biomarker - We discovered a blood neutrophil inflammation signature in the blood of patients with COVID-19 infection that can be targeted for treatment of this dangerous disease.
2. Antibodies that cause clots - We discovered that antibodies triggered by COVID-19 can cause clots...yet another way COVID is damaging.
2. Antibodies that cause clots - We discovered that antibodies triggered by COVID-19 can cause clots...yet another way COVID is damaging.
3. COVID DICER Clinical Trial - We started a randomized, clinical trial to test whether dipyridamole can reduce the severity of COVID.
3. COVID DICER Clinical Trial - We started a randomized, clinical trial to test whether dipyridamole can reduce the severity of COVID.
DEEP VEIN THROMBOSIS
DEEP VEIN THROMBOSIS
Our laboratory studies disease mechanisms in venous thrombosis with a major area of focus on regulation of venous homeostasis. We are exploring endogenous vasculo-protective enzymes that function at the intersection of inflammation and coagulation. We are also interested in disease pathways that are triggered by abnormal innate immune activation and cell stress responses that lead to an imbalance in coagulation and fibrinolysis. Our work utilizes human vascular cells and tissues from patients with vascular disease, primary cultures endothelial cells, and mouse models of venous thrombosis.
Our laboratory studies disease mechanisms in venous thrombosis with a major area of focus on regulation of venous homeostasis. We are exploring endogenous vasculo-protective enzymes that function at the intersection of inflammation and coagulation. We are also interested in disease pathways that are triggered by abnormal innate immune activation and cell stress responses that lead to an imbalance in coagulation and fibrinolysis. Our work utilizes human vascular cells and tissues from patients with vascular disease, primary cultures endothelial cells, and mouse models of venous thrombosis.
VEIN GRAFT DISEASE
VEIN GRAFT DISEASE
Veins are the most commonly used conduit to surgically bypass arterial stenoses. Veins are structurally distinct from arteries, and are forced to adapt to the arterial environment when used as arterial bypass grafts. Unfortunately, this remodeling can be pathologic and a high proportion of vein bypass grafts will fail, leading to ischemia or additional procedures. We are specifically studying the effect of extracellular nucleotide signalling in vein graft maladaptation. Using state-of-the-art mechanical stretch models that mimic vein graft function and mouse models of vein graft disease, our investigative efforts have focused on venous adaptations to arterial environments.
Veins are the most commonly used conduit to surgically bypass arterial stenoses. Veins are structurally distinct from arteries, and are forced to adapt to the arterial environment when used as arterial bypass grafts. Unfortunately, this remodeling can be pathologic and a high proportion of vein bypass grafts will fail, leading to ischemia or additional procedures. We are specifically studying the effect of extracellular nucleotide signalling in vein graft maladaptation. Using state-of-the-art mechanical stretch models that mimic vein graft function and mouse models of vein graft disease, our investigative efforts have focused on venous adaptations to arterial environments.
Funding sources
Funding sources
National Institutes of Health
National Institutes of Health
National Heart, Lung & Blood Institute
National Heart, Lung & Blood Institute
K08 HL131993-01 (September 2016)
K08 HL131993-01 (September 2016)
R01 R01HL150392-01 (March 2020)
R01 R01HL150392-01 (March 2020)
Falk Catalyst Award
Falk Catalyst Award
Lasker Investigator, NHLBI (start June, 2020)
Lasker Investigator, NHLBI (start June, 2020)
American Venous Forum -JOBST AWARD
American Venous Forum -JOBST AWARD
Bo Schembechler Heart of A Champion Foundation
Bo Schembechler Heart of A Champion Foundation
McKay Foundation
McKay Foundation
AC Forum - Ansell Fellowship Program
AC Forum - Ansell Fellowship Program
University of Michigan BioInterfaces Institute
University of Michigan BioInterfaces Institute
University of Michigan Frankel Cardiovascular Center
University of Michigan Frankel Cardiovascular Center
Page updated
Report abuse